Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study
QT interval prolongation is common in patients with DR-TB treated with bedaquiline-containing regimens, but the incidence of discontinuation is low. The concomitant use of clofazimine and the occurrence of hypokalemia during treatment will increase the risk of adverse cardiac events. It is recommended routine electrolyte monitoring, aggressive potassium supplementation, and cautious co-prescription of clofazimine or other QT-prolonging drugs for DR-TB patients on bedaquiline.
Authors
- Cui Xue-yi
- Yanxia Huang (ORCID: https://orcid.org/0000-0002-5690-9649)
- Hong Zhang (ORCID: https://orcid.org/0000-0003-4179-5666)
- Muhammad Tahir Khan (ORCID: https://orcid.org/0000-0003-1158-2133)
- Jinxing Huan
- Haobin Kuang (ORCID: https://orcid.org/0009-0003-7254-5149)
- Min Wang (ORCID: https://orcid.org/0000-0002-4067-9068)
- Feng Zhiyu
- Huang Xianlin
Institutions
- University of Lahore (PK)
- Center for Tuberculosis Control of Guangdong Province (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Guangzhou Chest Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Cardiology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1159/000549659
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00